The stock of Astrazeneca plc ADR (NASDAQ:AZN) last traded at $74.42, down -0.77% from the previous session.
AZN stock price is now 6.50% away from the 50-day moving average and 3.33% away from the 200-day moving average. The market capitalization of the company currently stands at $230.80B.
With the price target of $75, Exane BNP Paribas recently initiated with Outperform rating for Astrazeneca plc ADR (NASDAQ: AZN). , while ‘Morgan Stanley’ rates the stock as ‘Overweight’
A total of 0.01% of the company’s stock is owned by insiders.
During the past 12 months, Astrazeneca plc ADR has had a low of $61.24 and a high of $87.68. As of last week, the company has a debt-to-equity ratio of 0.77, a current ratio of 0.90, and a quick ratio of 0.70. According to the stock market information, the enterprise value for the company is $141765001216, which is based on a 29.90 price-to-earnings ratio, a 2.63 price-to-earnings-growth ratio, and a beta of 0.39. The fifty day moving average price for AZN is $69.8784 and a two-hundred day moving average price translates $72.02345 for the stock.
The latest earnings results from Astrazeneca plc ADR (NASDAQ: AZN) was released for 2025-03-31. The net profit margin was 14.14% and return on equity was 19.81% for AZN. The company reported revenue of $13.59 billion for the quarter, compared to $12.68 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.17 percent. For the current quarter, analysts expect AZN to generate $14.08B in revenue.
